Galil Medical Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Galil Medical Inc.
Not all of the key medtech deals of 2016 were blockbusters. Herein are some of the more interesting smaller deals of the year.
UK-listed BTG PLC shares the UK life science industry's concerns about long-term negative fallout from Brexit, but it finds itself in a relatively comfortable position. The acquisitive interventional medicines company says it has plenty of firepower for more M&A.
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.
Use of ablation technology is emerging as a potentially gentler treatment option for breast cancer, and cryo and thermal ablation in particular are on the verge of regulatory approval that could lead to wider use. A growing number of physicians are already using cryotherapy for breast cancer, but without FDA clearance, reimbursement can be a difficult issue.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.